|
Phase I-II Study of HER2 Vaccination with poly(I) • poly(C-12-U)(Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients Scientific DescriptionClinical Description |
Breast Cancer
Clinical Trials Contact
For more information regarding our trials, please call our Patient Coordinator
Stephanie Parker
866-932-8588
Email